Pharma Expanse is a leading provider of contract development and manufacturing services for pharmaceutical and biotech companies. Pharma Expanse is partnered with multiple Contract Development & Manufacturing Organizations (CDMOs) supporting manufacturing of RSMs, APIs, Drug Product and Cell Therapies. Pharma Expanse has drug product capabilities across a number of modalities including small molecules, biologics, ADCs, peptides, and nucleic acids (mRNA). Cell Therapy capabilities include cell line development, master cell banking and GMP manufacturing of allogeneic induced Pluripotent Stem Cells (iPSCs) for oncology and regenerative medicine.

The Pharma Expanse network currently spans across 20 manufacturing sites in 8 countries and can support discovery, preclinical, clinical, and commercial programs for New Chemical Entities (NCEs). Pharma Expanse operates as an integral part of the CDMO teams and is not a broker/agent. Pharma Expanse has an innovative business model that does not add additional costs to your project. Save your valuable time by streamlining your interactions with Pharma Expanse. 

Get in touch with Pharma Expanse to discuss development and manufacturing capabilities for your clinical and commercial programs or to request a proposal for manufacturing. Simplify outsourcing with Pharma Expanse! Contact us at info@PharmaExpanse.com to schedule a meeting.

The Pharma Expanse network currently spans across 20 manufacturing sites in 8 countries and can support discovery, preclinical, clinical, and commercial programs for New Chemical Entities (NCEs). Cell Therapy capabilities include cell line development, master cell banking, and GMP manufacturing of allogeneic induced Pluripotent Stem Cells (iPSCs) for oncology and regenerative medicine. Review our network’s detailed Cell Therapy Capabilities below:

Cell Line Development & Platform Technologies (iPSCs): 

• Readily available, immune-cloaked iPSC master cell lines derived from primary CD34 or CD4+ T-cells, ready for immediate use

• Cell lines are manufactured under GMP using proprietary IP in regenerative medicine, immune-evasive CAR-T and NK cell therapies, and tissue engineering

• Proprietary gene-editing CRISPR technology that delivers multiple gene edits in a single round and reliable delivery of large genetic payloads

• Innovative Co-Development model for creating new allogeneic, cell therapy assets for your pipeline

GMP Manufacturing (iPSC to Drug Product) - Platform Technologies & CDMO Activities (iPSCs):

Oncology

• High-yield platform for iPSC-NK manufacturing

• Allogeneic T-cell therapies – including α/β T cells and Tregs

• Differentiation and characterization of iPSC-Derived T Cells

Regenerative Medicine

• GMP manufacturing platform that delivers clinical grade, high-purity iPSC-derived cardiomyocytes
• Pre-established iPSC-to-endothelial differentiation process with scalable GMP manufacturing and a complete CMC framework

Facilities

• GMP Facility with GMP bioreactors from 2L to 100L
• 9 GMP cleanrooms
• 5 Cell Line Development Suites
• 6 Process Development Labs